GÃ©rald Simonneau

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10380099/publications.pdf

Version: 2024-02-01

336	85,082	735 120	344 285
papers	citations	h-index	g-index

350	350	350	26159
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119.	1.7	17
2	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	6.7	83
3	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. Annals of Cardiothoracic Surgery, 2022, 11, 143-150.	1.7	6
4	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	2.9	2
5	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	6.7	12
6	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
7	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2021, 177, 106293.	2.9	11
8	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
9	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	10.7	85
10	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	5.6	94
11	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Research, 2021, 7, 00850-2020.	2.6	65
12	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.8	21
13	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	4.7	3
14	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
15	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. Journal of Heart and Lung Transplantation, 2021, 40, 1009-1018.	0.6	24
16	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180.	0.6	9
17	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2021, 78, 1393-1403.	2.8	90
18	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287

#	Article	IF	Citations
19	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	6.7	50
20	Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12.	1.7	6
21	Sexâ€specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. Journal of Thrombosis and Haemostasis, 2020, 18, 151-161.	3.8	42
22	Survival Improved in Patients AgedÂâ‰ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.8	13
23	Assessment of the REPLACE study composite endpoint in riociguatâ€treated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8.	1.7	4
24	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000673.	6.7	35
25	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	5.6	12
26	Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340.	6.7	40
27	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.6	39
28	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131.	2.9	24
29	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295.	0.6	62
30	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	2.2	8
31	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842.	0.6	57
32	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095.	6.7	173
33	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
34	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	6.7	15
35	Initial combination therapy with ambrisentanâ€¯+â€¯tadalafil on pulmonary arterial hypertensionâ€'related hospitalization in the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 194-202.	0.6	19
36	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	7.1	40

#	Article	IF	Citations
37	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801913.	6.7	2,583
38	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	2.6	17
39	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	2.8	82
40	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164.	3.3	42
41	Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1364-1365.	5.6	0
42	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	2.2	69
43	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541.	5.6	12
44	Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 704-706.	5.6	6
45	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
46	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.6	15
47	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
48	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.8	68
49	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	6.7	21
50	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	6.7	60
51	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2018, 154, 521-531.	0.8	22
52	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	2.5	47
53	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	2.5	29
54	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43

#	Article	IF	Citations
55	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.8	10
56	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110.	0.6	20
57	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	2.5	33
58	Snoring and Obstructive Sleep Apnea: Objective Efficacy and Impact of a Chairside Fabricated Mandibular Advancement Device. Journal of Prosthodontics, 2017, 26, 381-386.	3.7	10
59	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	10.7	123
60	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.9	135
61	Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2017, 49, 1602522.	6.7	32
62	Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 925-928.	5.6	49
63	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart, 2017, 103, 599-606.	2.9	34
64	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	10.7	99
65	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	1.3	29
66	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 1234-1242.	0.6	37
67	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	3.9	56
68	The pathophysiology of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160112.	7.1	307
69	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22.	2.9	15
70	Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	7.3	68
71	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125.	14.6	386
72	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	6.7	97

#	Article	IF	Citations
73	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	10.7	201
74	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	6.7	113
75	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	6.7	89
76	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	6.7	527
77	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	7.1	48
78	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	1.7	25
79	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398.	0.6	15
80	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. Journal of Clinical Monitoring and Computing, 2017, 31, 903-910.	1.6	3
81	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.8	46
82	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	2.2	65
83	The changing landscape of chronic thromboembolic pulmonary hypertension management. European Respiratory Review, 2017, 26, 170105.	7.1	69
84	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Medicine, 2017, 17, 216.	2.0	23
85	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget, 2017, 8, 52995-53016.	1.8	42
86	Quality of life in patients with chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2016, 48, 526-537.	6.7	52
87	Future perspectives in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 381-389.	7.1	17
88	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68
89	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
90	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	6.7	124

#	Article	IF	Citations
91	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 647-656.	0.6	10
92	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
93	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 372-380.	10.7	130
94	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	10.7	59
95	Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads?. Annals of the American Thoracic Society, 2016, 13, S255-S258.	3.2	6
96	Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444.	6.7	44
97	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361.	0.8	55
98	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
99	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
100	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. Drug Safety, 2016, 39, 287-294.	3.2	35
101	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	6.7	87
102	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	2.2	5,074
103	A prospective study of the 6â€…min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ¯ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.9	16
104	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	8.2	208
105	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. Chest, 2015, 147, 1385-1394.	0.8	33
106	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	6.7	39
107	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	1.0	46
108	Rare (pulmonary) disease day: â€œfeeding the breath, energy for life!â€• European Respiratory Journal, 2015, 45, 297-300.	6.7	7

#	Article	IF	Citations
109	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214.	6.7	5
110	Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416.	1.9	26
111	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	27.0	790
112	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 1366-1375.	0.6	103
113	Response to Letter Regarding Article, â€œAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertensionâ€. Circulation, 2015, 132, e154.	1.6	3
114	Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function inÂPulmonary Hypertension. Journal of the American College of Cardiology, 2015, 65, 668-680.	2.8	119
115	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
116	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
117	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. European Journal of Cardio-thoracic Surgery, 2015, 47, e105-e110.	1.4	124
118	Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	1.7	10
119	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 348-355.	0.6	13
120	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
121	Safety of Therapeutic Doses of Tinzaparin During Pregnancy. Gynecologic and Obstetric Investigation, 2015, 79, 256-262.	1.6	4
122	Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164.	6.7	82
123	New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131.	1.8	20
124	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.	6.7	2,415
125	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844.	27.0	906
126	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80

#	Article	IF	Citations
127	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal, 2015, 45, 1293-1302.	6.7	247
128	Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8.	4.1	51
129	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	2.2	27
130	Key Role of the Endothelial TGF-Î²2/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension. PLoS ONE, 2014, 9, e100310.	2.5	83
131	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072.	6.7	43
132	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697.	6.7	319
133	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. Circulation, 2014, 130, 2189-2208.	1.6	278
134	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. European Respiratory Journal, 2014, 44, 1275-1288.	6.7	201
135	New horizons in pulmonary arterial hypertension management. European Respiratory Review, 2014, 23, 408-409.	7.1	3
136	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634.	6.7	80
137	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. European Respiratory Review, 2014, 23, 260-263.	7.1	3
138	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 689-697.	0.6	23
139	Reply. Journal of the American College of Cardiology, 2014, 63, 2882-2883.	2.8	3
140	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. International Journal of Cardiology, 2014, 172, 332-339.	1.7	47
141	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nature Genetics, 2014, 46, 65-69.	21.4	351
142	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
143	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 915-917.	6.7	111
144	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65.	3.6	38

#	Article	IF	Citations
145	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. International Journal of Cardiology, 2014, 172, 561-567.	1.7	28
146	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217.	2.7	59
147	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2014, 8, 84-92.	2.6	7
148	Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thrombosis and Haemostasis, 2014, 112, 598-605.	3.4	271
149	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 319-329.	27.0	1,144
150	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205.	3.3	22
151	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	27.0	1,168
152	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	2.8	541
153	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D34-D41.	2.8	2,865
154	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	2.8	518
155	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
156	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 1128-1138.	1.6	482
157	A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 756-759.	5.6	40
158	Riociguat for Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 2266-2268.	27.0	21
159	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521.	21.4	93
160	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
161	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	6.7	92
162	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2013, 41, 224-232.	6.7	100

#	Article	IF	Citations
163	Drug-induced pulmonary arterial hypertension: a recent outbreak. European Respiratory Review, 2013, 22, 244-250.	7.1	81
164	Chronic thromboembolic pulmonary hypertension: role of medical therapy. European Respiratory Journal, 2013, 41, 985-990.	6.7	99
165	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases, 2013, 72, 1940-1946.	0.9	128
166	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. Respiration, 2013, 85, 471-477.	2.6	20
167	Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure. Respiration, 2013, 85, 464-470.	2.6	15
168	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. European Respiratory Review, 2013, 22, 217-226.	7.1	68
169	Estimating Right Ventricular Stroke Work and the Pulsatile Work Fraction in Pulmonary Hypertension. Chest, 2013, 143, 1343-1350.	0.8	34
170	A paradigm shift in pulmonary arterial hypertension management. European Respiratory Review, 2013, 22, 423-426.	7.1	3
171	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Chest, 2013, 144, 1512-1520.	0.8	26
172	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. European Respiratory Review, 2013, 22, 487-494.	7.1	47
173	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2013, 110, 83-91.	3.4	96
174	The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats. PLoS ONE, 2013, 8, e77073.	2.5	11
175	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. European Respiratory Journal, 2012, 40, 630-640.	6.7	80
176	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Annals of the Rheumatic Diseases, 2012, 71, 596-605.	0.9	41
177	Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172.	6.7	75
178	Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270.	7.1	12
179	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83.	6.7	53
180	Human Immunodeficiency VirusnefSignature Sequences Are Associated with Pulmonary Hypertension. AIDS Research and Human Retroviruses, 2012, 28, 607-618.	1.1	50

#	Article	IF	Citations
181	Updated Clinical Classification of Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 1-13.	0.1	0
182	Pulmonary Hypertension in Sickle Cell Disease. Progress in Respiratory Research, 2012, , 137-142.	0.1	0
183	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550.	6.7	13
184	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.8	50
185	Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Chest, 2012, 142, 1150-1157.	0.8	104
186	Tadalafil for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2012, 60, 768-774.	2.8	124
187	Dysregulated Reninâ€“Angiotensinâ€“Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 780-789.	5.6	309
188	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. Annals of Thoracic Surgery, 2012, 94, 817-824.	1.3	116
189	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158.	0.6	91
190	Pre-implantation genetic diagnosis in pulmonary arterial hypertension due toBMPR2mutation: Figure 1â€“. European Respiratory Journal, 2012, 39, 1534-1535.	6.7	35
191	The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238.	7.1	15
192	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 874-880.	6.7	267
193	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
194	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2011, 30, 632-643.	0.6	95
195	Pulmonary veno-occlusive disease: The bÃªte noire of pulmonary hypertension in connective tissue diseases?. Presse Medicale, 2011, 40, e87-e100.	1.9	25
196	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 1585-1596.	1.8	23
197	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 702-710.	0.8	605
198	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211.	1.0	60

#	Article	IF	Citations
199	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respiratory Research, 2011, 12, 119.	3.6	67
200	Systemic sclerosisâ€“related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464.	6.7	109
201	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longâ€term survival. Arthritis and Rheumatism, 2011, 63, 3522-3530.	6.7	291
202	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 311-322.	2.9	125
203	Corrigendum to: "Guidelines for the diagnosis and treatment of pulmonary hypertension" [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926.	2.2	60
204	C-Kitâ€“Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123.	5.6	176
205	Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology, 2011, 8, 526-538.	13.7	125
206	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Circulation, 2011, 124, 1973-1981.	1.6	860
207	A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine, 2011, 365, 44-53.	27.0	432
208	Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure. Chest, 2011, 140, 1066-1068.	0.8	8
209	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. Chest, 2011, 140, 1274-1283.	0.8	237
210	Pulmonary hypertension associated with portal hypertension. , 2011, , 245-250.		0
211	Pulmonary hypertension related to appetite suppressants. , 2011, , 236-244.		0
212	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75.	2.2	149
213	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest, 2010, 137, 1297-1303.	0.8	46
214	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Current Opinion in Pulmonary Medicine, 2010, 16, S11-S19.	2.6	31
215	Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Current Opinion in Pulmonary Medicine, 2010, 16, S43-S46.	2.6	10
216	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. Current Opinion in Pulmonary Medicine, 2010, 16, S21-S26.	2.6	4

#	Article	IF	Citations
217	Long-term outcome of double-lung and heartâ€“lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patientsâ˜†. European Journal of Cardio-thoracic Surgery, 2010, 38, 277-284.	1.4	130
218	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respiratory Research, 2010, 11, 73.	3.6	81
219	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500.	1.9	91
220	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology, 2010, 49, 940-944.	1.9	53
221	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 1898-1907.	2.2	218
222	Vasodilators in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 202-203.	5.6	12
223	Classification de lâ€™hypertension pulmonaire. Archives of Cardiovascular Diseases Supplements, 2010, 2, 132-136.	0.0	0
224	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 851-861.	5.6	259
225	Pulmonary veno-occlusive disease: Recent progress and current challenges. Respiratory Medicine, 2010, 104, S23-S32.	2.9	94
226	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, S74-S80.	2.9	11
227	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264
228	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
229	Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. Chest, 2009, 135, 760-768.	0.8	102
230	Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 411-420.	2.1	37
231	Pulmonary Arterial Hypertension and HIV Infection. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 440-447.	2.1	19
232	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy, 2009, 26, 813-825.	2.9	96
233	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	2.2	3,108
234	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54.	2.8	1,919

#	Article	IF	Citations
235	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	2.8	62
236	GuÃa de prÃ¡ctica clÃnica para el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1464.e1-1464.e58.	0.6	2
237	Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2894-2903.	1.6	956
238	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. Journal of Clinical Investigation, 2009, 119, 512-523.	8.2	177
239	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219.	0.8	117
240	Immunosuppressive therapy in lupusâ€•and mixed connective tissue diseaseâ€“associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€‘three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
241	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.	2.8	506
242	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	5.6	405
243	Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2008, 2, 249-265.	2.6	33
244	Bosentan in mild pulmonary hypertension â€“ Authors' reply. Lancet, The, 2008, 372, 1731-1732.	13.7	0
245	Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 108-113.	5.6	402
246	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383.	5.6	269
247	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	5.6	220
248	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	1.0	295
249	Editors' perspective and conclusions. Aids, 2008, 22, S63-S67.	2.2	0
250	Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2008, 149, 521.	3.9	558
251	Pulmonary arterial hypertension and its association with HIV infection: an overview. Aids, 2008, 22, S1-S6.	2.2	21
252	Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1041-1047.	5.6	196

#	Article	IF	Citations
253	Pulmonary Arterial Hypertension: A Rare Complication of Primary SjÃ¶gren Syndrome. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	160
254	Endothelin-1/Endothelin-3 Ratio. Chest, 2007, 131, 101-108.	0.8	64
255	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	1.9	77
256	Diagnostic value of D-dimer in patients with suspected pulmonary embolism: Results from a multicentre outcome study. Thrombosis Research, 2007, 120, 195-200.	1.7	33
257	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.6	126
258	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902.	2.0	291
259	The French registry of pulmonary arterial hypertension in children: rationale and design. Current Medical Research and Opinion, 2007, 23, S27-S33.	1.9	6
260	Medical Therapy for Pulmonary Arterial Hypertension. Chest, 2007, 131, 1917-1928.	0.8	477
261	Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. Journal of Rheumatology, 2007, 34, 2417-22.	2.0	152
262	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	1.3	277
263	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest, 2006, 130, 182-189.	0.8	316
264	Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	2.5	368
265	BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Human Mutation, 2006, 27, 212-213.	2.5	196
266	Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 798-802.	5.6	83
267	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	2.2	272
268	Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension. Proceedings of the American Thoracic Society, 2006, 3, 608-614.	3.5	82
269	Angiopoietin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1025-1033.	5.6	106
270	The Need for National Registries in Rare Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 228a-229.	5.6	1

#	Article	IF	Citations
271	Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2006, 113, 2011-2020.	1.6	791
272	Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. Circulation, 2006, 113, 1857-1864.	1.6	257
273	Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2006, 7, 1133-1138.	1.8	2
274	Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1023-1030.	5.6	1,736
275	Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. Proceedings of the American Thoracic Society, 2006, 3, 601-607.	3.5	48
276	New Formula for Predicting Mean Pulmonary Artery Pressure. Chest, 2005, 128, 467.	0.8	4
277	Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. Chest, 2005, 128, 552S-553S.	0.8	17
278	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
279	Severe Pulmonary Hypertension during Pregnancy. Anesthesiology, 2005, 102, 1133-1137.	2.5	483
280	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040
281	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nature Clinical Practice Rheumatology, 2005, 1, 93-101.	3.2	16
282	Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opinion on Pharmacotherapy, 2005, 6, 1337-1348.	1.8	14
283	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 2148-2157.	27.0	2,237
284	Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 529-535.	2.8	441
285	Bosentan for the Treatment of Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1212-1217.	5.6	238
286	Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease. American Journal of Roentgenology, 2004, 183, 65-70.	2.2	234
287	Sildenafil for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 6-7.	5.6	22
288	New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure. Chest, 2004, 126, 1313-1317.	0.8	923

#	Article	IF	Citations
289	Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension. Circulation Research, 2004, 94, 1263-1270.	4.5	187
290	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	2.2	903
291	Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12.	2.8	1,542
292	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S81-S88.	2.8	206
293	Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2004, 351, 1425-1436.	27.0	1,627
294	Surgical Treatments/Interventions for Pulmonary Arterial Hypertension. Chest, 2004, 126, 63S-71S.	0.8	144
295	Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Chest, 2004, 126, 420-427.	0.8	232
296	Medical Therapy For Pulmonary Arterial Hypertension. Chest, 2004, 126, 35S-62S.	0.8	592
297	The CX3C chemokine fractalkine in allergic asthma and rhinitis. Journal of Allergy and Clinical Immunology, 2003, 112, 1139-1146.	2.9	82
298	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 41, 1380-1386.	2.8	334
299	Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension. Chest, 2003, 124, 247-254.	0.8	271
300	Prognostic Factors for Survival in Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1433-1439.	5.6	295
301	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	27.0	1,626
302	Pulmonary Artery Pressureâ€“Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 338-340.	5.6	94
303	Chemokine RANTES in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 534-539.	5.6	239
304	New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216.	5.6	129
305	CX₃C Chemokine Fractalkine in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1419-1425.	5.6	247
306	Pulse wave reflection in pulmonary hypertension. Journal of the American College of Cardiology, 2002, 39, 743.	2.8	9

#	Article	IF	Citations
307	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	2.8	584
308	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 40, 780-788.	2.8	1,290
309	Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2002, 346, 896-903.	27.0	2,545
310	Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet, The, 2002, 360, 1914-1920.	13.7	384
311	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research, 2002, 63, 227-246.	1.2	32
312	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 800-804.	5.6	1,288
313	Primary pulmonary hypertension: Current therapy. Progress in Cardiovascular Diseases, 2002, 45, 115-128.	3.1	54
314	Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. Journal of the American College of Cardiology, 2001, 37, 1085-1092.	2.8	151
315	RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 459-475.	2.1	116
316	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet, The, 2001, 358, 1119-1123.	13.7	1,421
317	PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 451-458.	2.1	153
318	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 2001, 345, 325-334.	27.0	676
319	Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation, 2001, 108, 1141-1150.	8.2	446
320	Systematic Lung Scans Reveal a High Frequency of Silent Pulmonary Embolism in Patients With Proximal Deep Venous Thrombosis. Archives of Internal Medicine, 2000, 160, 159.	3.8	197
321	High Prevalence of Detectable Deep Venous Thrombosis in Patients With Acute Pulmonary Embolism. Chest, 1999, 116, 903-908.	0.8	163
322	Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 1999, 16, 38-43.	1.4	63
323	Treatments for severe pulmonary hypertension. Lancet, The, 1999, 353, 338-340.	13.7	24
324	A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis. New England Journal of Medicine, 1998, 338, 409-416.	27.0	1,676

#	Article	IF	Citations
325	Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1681-1685.	5.6	161
326	Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1061-1067.	5.6	102
327	Chemokine Macrophage Inflammatory Protein-1Î± mRNA Expression in Lung Biopsy Specimens of Primary Pulmonary Hypertension. Chest, 1998, 114, 50S-51S.	0.8	68
328	Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives. Chest, 1998, 114, 195S-199S.	0.8	97
329	A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism. New England Journal of Medicine, 1997, 337, 663-669.	27.0	767
330	Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home. New England Journal of Medicine, 1996, 334, 682-687.	27.0	1,108
331	Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. New England Journal of Medicine, 1996, 335, 609-616.	27.0	1,127
332	Surgical Management of Unresolved Pulmonary Embolism. Chest, 1995, 107, 52S-55S.	0.8	51
333	Increased plasma serotonin in primary pulmonary hypertension. American Journal of Medicine, 1995, 99, 249-254.	1.5	500
334	Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin. American Journal of Medicine, 1990, 89, 117-120.	1.5	154
335	Cardiopulmonary Effects of a Single Oral Dose of Almitrine at Rest and on Exercise in Patients with Hypoxic Chronic Airflow Obstruction. Chest, 1986, 89, 174-179.	0.8	32
336	Inhibition of Hypoxic Pulmonary Vasoconstriction by Nifedipine. New England Journal of Medicine, 1981, 304, 1582-1585.	27.0	256